Biotech

All Articles

OS Treatments refiles $6M IPO to money HER2 drug, preclinical ADCs

.OS Therapies will certainly list on the NYSE American supply substitution this morning via a $6.4 t...

ALX's waning CD47 response fee sends out stock spiraling down

.ALX Oncology's period 2 gastric cancer action fee has weakened. After observing its CD47 blocker ef...

Ionis axes eye ailment coming from aim ats of Roche-partnered possibility after data disappoint

.Another of Ionis Pharmaceuticals' key midphase readouts has disappointed requirements, urging the b...

Biogen's chief executive officer stated no high-risk deals in 2023. He prepares to be daring

.While Biogen's pharma peers are seeking for late-stage assets with little bit of danger, chief exec...

Instil refills pipe in $2B biobucks cope with ImmunOnco

.Instil Biography has been a biotech seeking a pipeline after it scrapped its lead resources over th...

Biogen leaves Denali Alzheimer's collab

.Biogen has restored civil rights to an early Alzheimer's condition system to Denali Therapeutics, g...

Takeda taps brand-new head of US oncology business-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of substantial leadership hirings, firings as...

Vertex, hammered through AATD again, drops 2 assets on discard stack

.Tip's attempt to handle an unusual hereditary disease has actually struck yet another misfortune. T...

Vir increases 3 T-cell engagers from Sanofi, gives up 25% of staff

.Vir Medical's second-quarter earnings record had not been except huge news. The firm welcomed a tri...

Galapagos pauses CAR-T tissue treatment trial over Parkinsonism scenario

.Galapagos has actually paused enrollment in a trial of a BCMA-directed CAR-T cell therapy, pumping ...